Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis
Vaccine, Volume 23, No. 11, Year 2005
Notification
URL copied to clipboard!
Description
We hypothesized that the ability of BCG vaccination to protect against Mycobacterium tuberculosis is less in hosts exposed to chronic helminthes infection compared to unexposed individuals. To test this hypothesis we evaluated the efficacy of BCG vaccination in protecting against M. tuberculosis challenge in Schistosoma mansoni pre-infected mice by analyzing their ability to limit the replication of TB bacilli in the lung and liver and the histology of lung sections. The results show that BCG vaccinated mice with prior S. mansoni infection show significantly higher number of colony forming units of TB bacilli as well as significant reduction in air exchange area in the lung compared to controls. In addition, spleen cells from S. mansoni infected mice were found to produce significantly less IFN-γ and nitric oxide when stimulated in vitro with PPD and several fold higher soluble egg antigen (SEA) and Concanavalin A induced IL-4 and IL-5 secretion. Taken together, our data show that S. mansoni infection reduces the protective efficacy of BCG vaccination against M. tuberculosis possibly by attenuation of protective immune responses to mycobacterial antigens and/or by polarizing the general immune responses to the Th2 profile. © 2004 Published by Elsevier Ltd.
Authors & Co-Authors
Elias, Daniel
Sweden, Solna
Department of Microbiology, Tumor and Cell Biology
Sweden, Solna
Public Health Agency of Sweden
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
Akuffo, Hannah Opokua
Sweden, Solna
Department of Microbiology, Tumor and Cell Biology
Pawlowski, A.
Sweden, Solna
Public Health Agency of Sweden
Haile, Melles
Sweden, Solna
Public Health Agency of Sweden
Schön, Thomas
Sweden, Linkoping
Linköpings Universitet
Britton, Sven F.F.
Sweden, Stockholm
Karolinska Institutet
Statistics
Citations: 194
Authors: 6
Affiliations: 5
Identifiers
Doi:
10.1016/j.vaccine.2004.09.038
ISSN:
0264410X
Research Areas
Environmental
Infectious Diseases